ICC Melanoma
50+
Downloads
Everyone
info
About this app
HOW TO MANAGE THE TOXICITY AND ASSESSING THE RESPONSE IN PATIENTS WITH melanoma immunotherapy
The melanoma immunotherapy is going through a phase of great development, thanks to the important achievements in many clinical trials, starting in 2010, following the introduction of antibodies to immunological checkpoint as CTLA-4, and, in particular, PD -1. The purpose of this project is to deepen the main scenarios of melanoma difficult patient management affection for antibody therapy ant-PD-1, through examples of interactive clinical situations.
The melanoma immunotherapy is going through a phase of great development, thanks to the important achievements in many clinical trials, starting in 2010, following the introduction of antibodies to immunological checkpoint as CTLA-4, and, in particular, PD -1. The purpose of this project is to deepen the main scenarios of melanoma difficult patient management affection for antibody therapy ant-PD-1, through examples of interactive clinical situations.
Updated on
Safety starts with understanding how developers collect and share your data. Data privacy and security practices may vary based on your use, region, and age. The developer provided this information and may update it over time.
No data shared with third parties
Learn more about how developers declare sharing
No data collected
Learn more about how developers declare collection
What's new
Corretto bug su autenticazione utente
